A nitrile oxide compound which is a compound represented by General Formula [I], in which a melting point is 25 C. to 300 C., and an equivalent of nitrile oxide is 1.0 to 4.5 mmol/g.

##STR00001##

In the general formula, s: an integer of 1 to 4; R.sup.1 and R.sup.2: a hydrocarbon group having 4 to 10 carbon atoms or a halogenated hydrocarbon group having 4 to 10 carbon atoms; X: a divalent hydrocarbon group, O, S, or N(R.sup.3); R.sup.3: a hydrogen atom or a hydrocarbon group having 1 to 6 carbon atoms; and A: an s-valent organic group.

Provided is a novel donor-acceptor type compound which emits light even in a solid state. The present invention provides an organic optical material comprising a complex formed from (1) a conjugated molecule having (a) at least one electron donating site, (b) at least one electron accepting site, and (c) at least one conjugated site in the same molecule and (2) a compound having a proton donating property or an electron pair accepting property, the complex having a non-covalent interaction at the electron accepting site, wherein the complex is solid at ordinary temperature; and the organic optical material has a property of emitting light having a maximum fluorescence wavelength which causes a Stokes shift having a value corresponding to 5% or more of the value of a maximum absorption wavelength from the maximum absorption wavelength toward the long wavelength side.

The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: ##STR00001##
which exhibits Acetyl-CoA carboxylase (ACC) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: ##STR00001##
which exhibits Acetyl-CoA carboxylase (ACC) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

Compounds and compositions are provided that can inhibit microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and compositions can reduce inflammation in a subject, such as inflammation caused by an inflammation disorder or symptoms thereof. Pharmaceutical compositions comprising the compound are also provided. Furthermore, methods are provided for reducing inflammation and/or inhibiting mPGES-1. The methods can comprise administering an effective amount of the composition to a subject.

Provided is a compound of Chemical Formula 1:

##STR00001##

where R.sub.1 and R.sub.2 are each independently hydrogen, a substituted or unsubstituted C.sub.1-60 alkyl, a substituted or unsubstituted C.sub.1-60 alkoxy, a substituted or unsubstituted C.sub.1-60 haloalkyl, a substituted or unsubstituted C.sub.1-60 haloalkoxy, halogen, cyano, tri(C.sub.1-60 alkyl)silyl, a substituted or unsubstituted C.sub.6-60 aryl, or a substituted or unsubstituted C.sub.2-60 heteroaryl containing at least one of O, N, Si and S,

R.sub.3 and R.sub.4 are each independently hydrogen, deuterium, a substituted or unsubstituted C.sub.1-60 alkyl, a substituted or unsubstituted C.sub.1-60 alkoxy, a substituted or unsubstituted C.sub.1-60 haloalkyl, a substituted or unsubstituted C.sub.1-60 haloalkoxy, halogen, cyano, tri(C.sub.1-60 alkyl)silyl, or a substituted or unsubstituted C.sub.2-60 heteroaryl containing at least one of O, N, Si and S, and

Ar is C.sub.6-60 aryl, or C.sub.2-60 heteroaryl containing at least one of O, N, Si and S, wherein the C.sub.6-60 aryl, or C.sub.2-60 heteroaryl is substituted with 1 to 5 substituents each selected from the group consisting of a substituted or unsubstituted C.sub.1-60 alkyl, a substituted or unsubstituted C.sub.1-60 alkoxy, a substituted or unsubstituted C.sub.1-60 haloalkyl, a substituted or unsubstituted C.sub.1-60 haloalkoxy, halogen, cyano, and tri(C.sub.1-60 alkyl)silyl,

and an organic light emitting device including the same.

The present disclosure provides solid forms, including a salt or co-crystal, of Compound I:

##STR00001##

which exhibits Acetyl-CoA carboxylase (ACC) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

The present disclosure provides solid forms, including a salt or co-crystal, of Compound I:

##STR00001##

which exhibits Acetyl-CoA carboxylase (ACC) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.

Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.

##STR00001##